DE69912760T2 - Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln - Google Patents
Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln Download PDFInfo
- Publication number
- DE69912760T2 DE69912760T2 DE69912760T DE69912760T DE69912760T2 DE 69912760 T2 DE69912760 T2 DE 69912760T2 DE 69912760 T DE69912760 T DE 69912760T DE 69912760 T DE69912760 T DE 69912760T DE 69912760 T2 DE69912760 T2 DE 69912760T2
- Authority
- DE
- Germany
- Prior art keywords
- use according
- oil
- cream
- galactolipid
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000463 material Substances 0.000 title claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 239000012049 topical pharmaceutical composition Substances 0.000 title claims abstract description 17
- 239000013543 active substance Substances 0.000 title claims abstract description 10
- 239000000839 emulsion Substances 0.000 title description 15
- 239000003795 chemical substances by application Substances 0.000 title description 5
- 230000005923 long-lasting effect Effects 0.000 title description 2
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 31
- 239000008346 aqueous phase Substances 0.000 claims abstract description 19
- 239000006071 cream Substances 0.000 claims description 63
- 239000003921 oil Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 19
- 239000006210 lotion Substances 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 14
- 230000000699 topical effect Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 239000007764 o/w emulsion Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 6
- 229940100611 topical cream Drugs 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 239000004909 Moisturizer Substances 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 230000002045 lasting effect Effects 0.000 claims description 5
- 230000001333 moisturizer Effects 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- KJXHHTPQSFDEKB-ZKMIVQISSA-N (9z,12e)-13-hydroxyoctadeca-9,12-dienoic acid Chemical compound CCCCC\C(O)=C/C\C=C/CCCCCCCC(O)=O KJXHHTPQSFDEKB-ZKMIVQISSA-N 0.000 claims description 3
- 229940030999 antipsoriatics Drugs 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 229940100617 topical lotion Drugs 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 235000019198 oils Nutrition 0.000 description 40
- 210000003491 skin Anatomy 0.000 description 26
- 239000012071 phase Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 17
- 230000003020 moisturizing effect Effects 0.000 description 15
- 206010013786 Dry skin Diseases 0.000 description 11
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 10
- 230000037336 dry skin Effects 0.000 description 10
- KDYAPQVYJXUQNY-OPHDRXFHSA-N 1,2-di-(alpha-linolenoyl)-3-[alpha-D-galactosyl-(1->6)-beta-D-galactosyl]-sn-glycerol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KDYAPQVYJXUQNY-OPHDRXFHSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 206010003645 Atopy Diseases 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001486234 Sciota Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- -1 des Steroids Chemical class 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 238000009499 grossing Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010040954 Skin wrinkling Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- HNICUWMFWZBIFP-KDFHGORWSA-N alpha-Artemisic acid Chemical compound CCCCCC(O)\C=C\C=C\CCCCCCCC(O)=O HNICUWMFWZBIFP-KDFHGORWSA-N 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940089020 evening primrose oil Drugs 0.000 description 3
- 239000010475 evening primrose oil Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241001295925 Gegenes Species 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000245063 Primula Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QZXMUPATKGLZAP-DXLAUQRQSA-N [(2S)-1-hexadecanoyloxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QZXMUPATKGLZAP-DXLAUQRQSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- KQNZLOUWXSAZGD-UHFFFAOYSA-N benzylperoxymethylbenzene Chemical compound C=1C=CC=CC=1COOCC1=CC=CC=C1 KQNZLOUWXSAZGD-UHFFFAOYSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011250 protective ointment Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9800729 | 1998-03-06 | ||
| SE9800729A SE9800729L (sv) | 1998-03-06 | 1998-03-06 | Ny topikal formulering I |
| PCT/SE1999/000347 WO1999044585A1 (en) | 1998-03-06 | 1999-03-08 | Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69912760D1 DE69912760D1 (de) | 2003-12-18 |
| DE69912760T2 true DE69912760T2 (de) | 2004-09-30 |
Family
ID=20410443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69912760T Expired - Lifetime DE69912760T2 (de) | 1998-03-06 | 1999-03-08 | Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1069886B1 (https=) |
| JP (1) | JP2002505272A (https=) |
| AT (1) | ATE253895T1 (https=) |
| AU (1) | AU750526B2 (https=) |
| CA (1) | CA2322850A1 (https=) |
| DE (1) | DE69912760T2 (https=) |
| DK (1) | DK1069886T3 (https=) |
| ES (1) | ES2211062T3 (https=) |
| NZ (1) | NZ506756A (https=) |
| PT (1) | PT1069886E (https=) |
| SE (1) | SE9800729L (https=) |
| WO (1) | WO1999044585A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005023640A1 (de) * | 2005-05-19 | 2006-11-23 | Beiersdorf Ag | Wirkstoffkombinationen aus Glucosylglyceriden und einem oder mehreren partiell neutralisierten Ester von Monoglyceriden und / oder Diglyceriden gesättigter Fettsäuren mit Zitronensäure |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2304906A1 (en) | 2000-04-07 | 2001-10-07 | 1411198 Ontario Limited | 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| EP1151745A1 (fr) * | 2000-05-05 | 2001-11-07 | L'oreal | Composition sous forme d'émulsion eau-dans-huile et ses utilisations cosmétiques |
| US20020165286A1 (en) * | 2000-12-08 | 2002-11-07 | Hanne Hedeman | Dermal anti-inflammatory composition |
| AU2003279622A1 (en) | 2002-06-28 | 2004-01-19 | Nitromed, Inc. | Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| KR101243526B1 (ko) * | 2004-08-31 | 2013-03-20 | 스티펠 리서치 오스트레일리아 피티와이 리미티드 | 마이크로에멀젼 및 서브마이크론 에멀젼 방법 및 조성물 |
| US8449867B2 (en) | 2004-08-31 | 2013-05-28 | Stiefel Research Australia Pty Ltd | Microemulsion and sub-micron emulsion process and compositions |
| PL1879466T5 (pl) * | 2005-03-04 | 2016-07-29 | Dsm Ip Assets Bv | Spożywcza cząsteczkowa kompozycja lipidowa |
| US20080260816A1 (en) * | 2005-09-16 | 2008-10-23 | Bengt Herslof | Particulate Lipid Pharmaceutical Composition |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| WO2008084253A1 (en) * | 2007-01-12 | 2008-07-17 | Lipopeptide Ab | Use of a galactolipid for wound and ulcer healing |
| US20100136124A1 (en) * | 2007-04-20 | 2010-06-03 | University Of South Australia | Nanoparticle-coated capsule formulation for dermal drug delivery |
| PT2496263T (pt) | 2009-11-03 | 2022-03-28 | Lipidor Ab | Composição que forma uma camada lipídica para administração sobre uma superfície de um organismo vivo |
| US8809307B2 (en) | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
| US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
| SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| JP2017529334A (ja) * | 2014-08-27 | 2017-10-05 | アッヴィ・インコーポレイテッド | 局所製剤 |
| US11617724B2 (en) | 2015-05-21 | 2023-04-04 | Dermavant Sciences GmbH | Topical pharmaceutical compositions |
| CN107666902B (zh) | 2015-05-21 | 2021-09-21 | 德玛万科学有限责任公司 | 局部药物组合物 |
| CN108282998B (zh) | 2015-06-18 | 2021-07-06 | 凡利亚药品北美公司 | 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物 |
| US11311482B2 (en) | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS597118A (ja) * | 1982-06-16 | 1984-01-14 | ユニリ−バ−・ナ−ムロ−ゼ・ベンノ−トシヤ−プ | 化粧用組成物 |
| JPS649908A (en) * | 1987-07-02 | 1989-01-13 | Kao Corp | Cosmetic, cosmetic set and make-up method |
| JPH0374316A (ja) * | 1989-08-11 | 1991-03-28 | Kanebo Ltd | 保湿剤 |
| JPH0818948B2 (ja) * | 1990-08-31 | 1996-02-28 | 花王株式会社 | 水性化粧料及びその製造法 |
| JPH0543465A (ja) * | 1991-08-08 | 1993-02-23 | Mitsubishi Kasei Corp | コルチコステロイド含有ローシヨン剤 |
| JPH069365A (ja) * | 1992-06-25 | 1994-01-18 | Kanebo Ltd | 皮膚化粧料 |
| PL176941B1 (pl) * | 1993-03-12 | 1999-08-31 | Axys Pharmaceuticals | Nowe peptydy i środek farmaceutyczny do leczenia immunologicznych stanów zapalnych |
| FR2710854B1 (fr) * | 1993-10-08 | 1995-12-01 | Oreal | Emulsion huile-dans-eau utilisable pour l'obtention d'une crème. |
| BR9506681A (pt) * | 1994-02-04 | 1997-11-18 | Scotia Lipidteknik Ab | Emulsão oleo em água e composição farmacêutica |
| SE9402453D0 (sv) * | 1994-07-12 | 1994-07-12 | Astra Ab | New pharmaceutical preparation |
| JPH08165244A (ja) * | 1994-10-12 | 1996-06-25 | Taisho Pharmaceut Co Ltd | 皮膚疾患治療剤 |
| ZA96525B (en) * | 1995-02-06 | 1996-08-06 | Astra Ab | Novel pharmaceutical compositions |
| SE504664C2 (sv) * | 1995-09-22 | 1997-03-24 | Scotia Lipidteknik Ab | Sätt att framställa fraktionerad olja, oljan, dess användning samt emulsionskomposition innehållande oljan |
| JP3326059B2 (ja) * | 1995-10-05 | 2002-09-17 | カネボウ株式会社 | 皮膚化粧料 |
-
1998
- 1998-03-06 SE SE9800729A patent/SE9800729L/xx not_active Application Discontinuation
-
1999
- 1999-03-08 DK DK99913784T patent/DK1069886T3/da active
- 1999-03-08 WO PCT/SE1999/000347 patent/WO1999044585A1/en not_active Ceased
- 1999-03-08 AU AU31778/99A patent/AU750526B2/en not_active Ceased
- 1999-03-08 JP JP2000534188A patent/JP2002505272A/ja active Pending
- 1999-03-08 ES ES99913784T patent/ES2211062T3/es not_active Expired - Lifetime
- 1999-03-08 NZ NZ506756A patent/NZ506756A/en unknown
- 1999-03-08 DE DE69912760T patent/DE69912760T2/de not_active Expired - Lifetime
- 1999-03-08 PT PT99913784T patent/PT1069886E/pt unknown
- 1999-03-08 CA CA002322850A patent/CA2322850A1/en not_active Abandoned
- 1999-03-08 AT AT99913784T patent/ATE253895T1/de not_active IP Right Cessation
- 1999-03-08 EP EP99913784A patent/EP1069886B1/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005023640A1 (de) * | 2005-05-19 | 2006-11-23 | Beiersdorf Ag | Wirkstoffkombinationen aus Glucosylglyceriden und einem oder mehreren partiell neutralisierten Ester von Monoglyceriden und / oder Diglyceriden gesättigter Fettsäuren mit Zitronensäure |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002505272A (ja) | 2002-02-19 |
| ES2211062T3 (es) | 2004-07-01 |
| WO1999044585A1 (en) | 1999-09-10 |
| AU750526B2 (en) | 2002-07-18 |
| EP1069886A1 (en) | 2001-01-24 |
| DE69912760D1 (de) | 2003-12-18 |
| SE9800729D0 (sv) | 1998-03-06 |
| PT1069886E (pt) | 2004-04-30 |
| EP1069886B1 (en) | 2003-11-12 |
| SE9800729L (sv) | 1999-09-07 |
| CA2322850A1 (en) | 1999-09-10 |
| ATE253895T1 (de) | 2003-11-15 |
| DK1069886T3 (da) | 2004-03-22 |
| NZ506756A (en) | 2003-10-31 |
| AU3177899A (en) | 1999-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69912760T2 (de) | Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln | |
| DE69232914T2 (de) | Topische Zubereitung, die eine Suspension von festen lipidischen Teilchen enthält | |
| DE60209213T2 (de) | Lichtdurchlässige Nanoemulsion, ihr Herstellungsverfahren und ihre Verwendungen in der Kosmetik, Dermatologie und/oder Ophthalmologie | |
| DE69500013T2 (de) | Reinigendes Mittel enthaltend lipidische Körner | |
| DE69413867T2 (de) | Mehrfachemulsionen, ihre Herstellung, ihre Verwendung zur Herstellung von kosmetischen Zubereitungen und diese kosmetischen Zubereitungen | |
| DE69400430T2 (de) | Kosmetische und/oder dermatologische Zusammensetzung enthaltend Salicylsäurederivate sowie ihren Verfahren zum Auflösen | |
| DE69400337T2 (de) | Mittel gegen Hautalterung, das gleichzeitig auf die Hautoberschichten und Tiefschichten wirkt | |
| DE69400333T2 (de) | Kosmetische und dermatologische Zusammensetzungen, die eine Kombination aus Ceramiden und Linolsäure enthalten | |
| EP1912624B1 (de) | Wasserfreies mehr-phasen-gel-system | |
| DE4021082C2 (de) | Hautbehandlungsmittel mit hohen Lipidgehalten unter Verwendung eines Bilayer enthaltenden Systems, Salzen organischer Säuren, Alkohol und Stabilisator | |
| DE69500315T2 (de) | Kosmetische oder dermatologische Wasser-in-Öl Emulsion mit hohem Gehalt an Hydroxysäuren | |
| DE602005002844T3 (de) | Umkehremulsionszusammensetzung mit calcitriol und clobetasol-17-propionat und ihre kosmetische und dermatologische verwendung | |
| EP1014916A2 (de) | Schaum-hautschutzcreme | |
| DE69600118T2 (de) | Verwendung der Benzosäurederivate zur Stimulierung die Erneuerung der Epidermis und zur Behandlung der Haut | |
| DE60133038T2 (de) | Hypoallergenisches nichtreizendes hautpflegemittel | |
| WO2023194557A1 (de) | Zusammensetzung zur behandlung der haut | |
| DE4021083A1 (de) | Phospholipidformulierungen und ihre verwendung fuer die zubereitung liposomaler medizinischer und kosmetischer baeder | |
| DE102011110749A1 (de) | Kosmetische oder pharmazeutische Zusammensetzung mit lamellaren Strukturen unter Verwendung von Sucrose-fettsäure-Triestern - einfache und leichte Herstellung | |
| DE19801593A1 (de) | Lipoprotein-Cremes | |
| US20050063930A1 (en) | Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance | |
| DE69904454T2 (de) | Topische formulierungen des öl-in-wasser typs als träger zur vermittlung eines reduzierten reizeffekts | |
| DE69713896T2 (de) | Pharmazeutische formulierungen zur topischen verwendung mit vit. e acetate | |
| DE4310015C2 (de) | Verfahren zur Herstellung eines Mittels zur Pflege der Haut | |
| DE102005008299B4 (de) | Kosmetische und/oder dermatologische Formulierung, Verfahren zu deren Herstellung und Verwendung der Formulierung | |
| DE60306584T2 (de) | Verwendung eines 7-oxidierten DHEA-Derivats zur Behandlung von trockener Haut |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8365 | Fully valid after opposition proceedings |